Aldosterone receptor Ppts and Published papers

Selective Aldosterone receptor Antagonist SARA
by John  A. Heit, MD
http://www.surgeongeneral.gov/topics/deepvein/workshop/presentations/heit_practice-patient.ppt

Drugs for Hypertension
http://www.mac.edu/faculty/christinestaake/Nursing%20311/Web%20Drugs%20for%20Hypertension%20Chapter%2023.ppt

Antihypertensives Approaches to  Hypertension Treatment
http://www.patheyman.com/sites/default/files/nursing/notes/06-CV2-BloodPressure-2.ppt

Evolution of  Steroid Receptor Gene Families
https://mywebspace.wisc.edu/carollee/web/Lee/611%202009%20ReadingWEB/11.EvolutionHormoneRecept2011.ppt

Got  Aldosterone? Aldosterone  Synthesis
http://medicine.med.nyu.edu/nephrology/files/med_nephrology/attachments/Got_Aldosterone.ppt

Aldosterone  and MR Activation Revisited   
by Philip  J. Klemmer, MD
http://www.med.unc.edu/medicine/web/8.28.07%20Aldosterone%20Klemmer.ppt

Adrenal Steroids:  A Review
http://www.calstatela.edu/faculty/mchen/439Lectures/439EnAdrenals14.ppt

Publications

1. Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry.
2. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
3. Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis.
4. Is GPR30 the membrane aldosterone receptor postulated 20 years ago?
5. Treatment considerations with aldosterone receptor antagonists.
6. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
7. Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty.
8. Possible interactive effect of testosterone and aldosterone receptor antagonists on cardiac apoptosis.
9. Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis.
10. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
11. Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats.
12. Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
13. Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.
14. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.
15. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.
16. Aldosterone receptor antagonists: effective but often forgotten.
17. Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats.
18. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
19. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.
20. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
21. Contribution of transgenesis models in discovery of new pharmacological targets in heart failure: aldosterone receptor as an example.
22. Aldosterone-receptor antagonism in hypertension.
23. Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not.
24. Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
25. Aldosterone receptor sites on plasma membrane of human vascular endothelium detected by a mechanical nanosensor.
26. The risks and benefits of therapy with aldosterone receptor antagonist therapy.
27. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
28. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
29. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
30. Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction.
31. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
32. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
33. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
34. Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure.
35. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats.
36. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
37. Myocardial structural effects of aldosterone receptor antagonism in heart failure.
38. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
39. The effect of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on cardiac function in calcium-overload rats.
40. Aldosterone receptor antagonists.
41. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
42. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
43. Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure.
44. Estrogen receptor activation--good, aldosterone receptor blockade--beneficial, communication between receptors...priceless.
45. Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension.
46. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
47. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.
48. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
49. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
50. Aldosterone receptor blockade after acute myocardial infarction with heart failure.